The AIM-traded firm said the contract was for a phase 1, open-label dose finding study which would assess the safety, tolerability, pharmacokinetics and preliminary efficacy of OBT076', a CD205-directed antibody-drug conjugate, in recurrent and metastatic CD205-positive solid tumours and in women with CD205-positive HER2-negative metastatic breast cancer
Copying/Pasting full or partial texts with adding very little original content are frowned upon by the community. Repeated copy/paste posts could be considered spam. Spam is discouraged by the community and may result in the account being Blacklisted.
Downvoting a post can decrease pending rewards and make it less visible. Common reasons:
Submit